MURALI CHINTAGUMPALA to Osteosarcoma
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Osteosarcoma.
Connection Strength
0.824
-
Risk-Based Therapy for Localized Osteosarcoma. Pediatr Blood Cancer. 2016 Mar; 63(3):412-7.
Score: 0.402
-
Plasma proteome predicts chemotherapy response in osteosarcoma patients. Oncol Rep. 2011 Feb; 25(2):303-14.
Score: 0.072
-
Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer. 2011 Jan 01; 117(1):207-17.
Score: 0.070
-
Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res. 2008 Jun; 6(6):937-46.
Score: 0.060
-
Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006 Jun; 6(11):3426-35.
Score: 0.052
-
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50.
Score: 0.050
-
Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer. 2004 Jan; 39(1):11-21.
Score: 0.044
-
Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003 May 07; 95(9):669-74.
Score: 0.042
-
Multifocal osteosarcoma: an unusual presentation. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):58-62.
Score: 0.031